CD Biosynsis provides expert Protein High Throughput Screening ( HTS ) Services to rapidly and efficiently identify proteins, antibodies, or peptides with desired binding properties, stability, or catalytic activity. Leveraging the power of modern display technologies, we can screen libraries containing 10^9 to 10^14 variants, significantly accelerating the discovery and engineering of novel biologics and industrial enzymes. Our platform includes Cell-Free systems ( Ribosome and mRNA display) for ultra-high throughput and speed, as well as robust cell-based systems ( Phage and Yeast display) for functional validation. We combine library generation, display, screening, and validated High-Throughput Binding Assays to deliver high-quality hits and leads.
Get a QuoteHigh Throughput Screening is a cornerstone of modern protein engineering, enabling the efficient exploration of vast diversity landscapes generated through directed evolution or combinatorial design. Display technologies link the phenotype (the displayed protein) to its genotype (the encoding DNA or RNA ), allowing for rapid cycles of selection and enrichment based on affinity, specificity, or stability. By offering both In Vitro (cell-free) and In Vivo (cell-based) display systems, we ensure that the optimal screening strategy is applied to any target, whether it requires ultra-large library sizes or display in a natural cellular context.
A generalized term for rapid in vitro display systems, enabling the screening of 10^12-10^14 variants.
Stable, non-covalent linkage of protein, mRNA , and ribosome complex for screening complex proteins and rapid re-engineering.
Covalent linkage of protein to its encoding mRNA via a puromycin linker, offering the highest throughput capacity ( up to 10^{14} ).
Presentation of proteins on the surface of bacteriophages, a highly robust method for screening antibodies ( scFv , Fab ) and peptides.
Display of proteins on the S. cerevisiae surface, enabling quantitative binding selection and sorting via FACS (Fluorescence-Activated Cell Sorting).
Advanced assays ( HT-SPR/BLI , ELISA -based) to rapidly characterize the binding kinetics and affinity ( Kd ) of selected hits.
Our tailored workflow combines library generation with highly sensitive selection and validation steps.
Library Design & Construction
Display Platform Execution
Selection & Enrichment
Characterization & Lead Generation
Consultation to define target properties (affinity, specificity).
Design of the mutagenesis strategy ( CDR randomization, saturation mutagenesis).
Construction of high-quality genetic libraries ( DNA/mRNA ) with high diversity and low bias.
Implementation onto the chosen display system ( Phage , Yeast , Ribosome , or mRNA display).
Optimization of display conditions to ensure high surface expression and proper folding.
Cloning of enriched candidates for soluble protein expression and purification.
Validation of binding properties using High-Throughput Binding Assays ( BLI/SPR ).
Detailed sequencing and functional data to confirm the activity of the final leads.
Ultra-High Diversity Capacity
Access to mRNA and Ribosome Display for screening libraries up to 10^14 variants, significantly increasing the chance of finding rare, high-affinity binders.
Quantitative Yeast Display ( FACS )
Utilizing FACS to sort yeast cells based on binding affinity, allowing for precise, quantitative selection of binders with desired Kd values.
Integrated Kinetic Validation
Immediate follow-up with High-Throughput BLI/SPR Assays to verify binding kinetics, saving time in moving from a 'hit' to a 'lead'.
Targeted Antibody & scFv Discovery
Expertise in specific library formats and display systems optimal for therapeutic antibody fragment discovery and affinity maturation.
"The mRNA Display service was incredibly fast. We screened 10^13 peptide variants and identified a novel, high-affinity binder against our target in less than three weeks, which was verified by their BLI assay."
Dr. Samuel Reyes, CTO , Peptide Therapeutics Lab
"Using their Yeast Surface Display platform and FACS sorting, we were able to precisely mature the affinity of our scFv from nM to pM range, an unprecedented success for our lead candidate."
Ms. Clara Dubois, R\&D Manager, Antibody Engineering Lab
"The combination of Phage Display for initial hits and High-Throughput Binding Assays for validation provided us with a clean, well-characterized set of leads for our diagnostic biomarker project."
Prof. Akira Sato, University Synthetic Biology Lab
"We commissioned CD Biosynsis to support an intricate gene editing project with multiple targets. Their talent in producing high-quality work in a short period of time was impressive. Their solutions were custom made to suit our needs, and they went above and beyond to ensure our experiments worked. Their support has been a great asset to our research department and we look forward to further working with them."
Dr. Raj Patel, Principal Investigator, Department of Molecular Biology
"As a pharmaceutical company working to discover new cancer therapies, we require accurate, trustworthy gene editing solutions. CD Biosynsis did more than what we expected when it came to providing strong, accurate CRISPR/Cas9 solutions for our preclinical research. Their technical support team was excellent and responsive, and they quickly replied to our questions. This alliance has been pivotal in helping us move our drug pipeline forward. Thank you, CD Biosynsis, for your amazing service!"
Dr. Clara Rodriguez, Chief Scientist, AstraZeneca Pharmaceuticals
What is the difference between mRNA and Ribosome Display?
mRNA Display creates a covalent bond between the expressed protein and its encoding mRNA using a puromycin linker, offering the highest library diversity ( up to 10^{14} ). Ribosome Display relies on a stable non-covalent bond between the protein, mRNA , and ribosome complex, often used for more complex or multi-domain proteins.
When is Yeast Surface Display ( YSD ) the preferred method?
YSD is preferred when quantitative affinity selection is critical. Its compatibility with FACS allows for precise, single-cell sorting based on binding signal, making it ideal for affinity maturation and selecting binders within a specific Kd range.
Can you screen against a non-protein target (e.g., small molecule, carbohydrate)?
Yes. All our display platforms can be adapted to screen against non-protein targets, provided the target can be immobilized or labeled (e.g., biotinylated small molecules) to allow for the physical selection or sorting of the displaying cells/phages/complexes.
What kind of data is provided by the High-Throughput Binding Assays ?
These assays (typically BLI or SPR ) provide key kinetic data, including the association rate ( ka ), the dissociation rate ( kd ), and the equilibrium dissociation constant ( Kd ), which is essential for determining the therapeutic or diagnostic viability of the lead candidates.
How much does Metabolic Engineering services cost?
The cost of Metabolic Engineering services depends on the project scope, complexity of the target compound, the host organism chosen, and the required yield optimization. We provide customized quotes after a detailed discussion of your specific research objectives.
Do your engineered strains meet regulatory standards?
We adhere to high quality control standards in all strain construction and optimization processes. While we do not handle final regulatory approval, our detailed documentation and compliance with best laboratory practices ensure your engineered strains are prepared for necessary regulatory filings (e.g., GRAS , FDA ).
What to look for when selecting the best gene editing service?
We provide various gene editing services such as CRISPR-sgRNA library generation, stable transformation cell line generation, gene knockout cell line generation, and gene point mutation cell line generation. Users are free to select the type of service that suits their research.
Does gene editing allow customisability?
Yes, we offer very customised gene editing solutions such as AAV vector capsid directed evolution, mRNA vector gene delivery, library creation, promoter evolution and screening, etc.
What is the process for keeping data private and confidential?
We adhere to the data privacy policy completely, and all customer data and experimental data are kept confidential.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.